Post-radical-treatment follow-up for localised prostate cancer — MSRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Measure PSA no earlier than 6 weeks, repeat it at least every 6 months for 2 years, without routine DRE while PSA is at baseline
Explanation lettering: E = shown as A · A = shown as B · B = shown as E
The first post-radical-treatment PSA should be checked no earlier than 6 weeks after treatment; at 4 weeks, testing is premature. NICE advises PSA measurement at least every 6 months for the first 2 years and at least annually thereafter. In a person with localised prostate cancer who is not on active surveillance, routine DRE is not recommended while the PSA remains at baseline levels. A is wrong because both the timing of PSA testing and routine DRE are inappropriate. B correctly limits DRE to a potentially indicated context, but still tests PSA too early. C has the correct initial PSA timing and 6-monthly interval, but routine DRE adds no value when PSA remains at baseline. E delays the initial PSA beyond the recommended earliest assessment and uses annual testing too soon after radical treatment. This question distinguishes surveillance after curative treatment from active-surveillance protocols, in which DRE and MRI can have defined roles.
Reference: NICE NG131: Prostate cancer: diagnosis and management, recommendations 1.3.47-1.3.48 (Published 2019; last updated 15 December 2021; last reviewed 13 August 2025) — https://www.nice.org.uk/guidance/ng131/chapter/Recommendations